Medifast, Inc.MEDNYSE
Loading
EBITDA Margin Over TimeContracting
Percentile Rank0
3Y CAGR-68.7%
5Y CAGR-52.0%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
-68.7%/yr
vs -4.4%/yr prior
5Y CAGR
-52.0%/yr
Recent deceleration
Acceleration
-64.2pp
Decelerating
Percentile
P0
Near historical low
vs 5Y Ago
0x
Contraction
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM0.38%-85.4%
20242.59%-80.1%
202313.01%+6.3%
202212.24%-16.2%
202114.62%-1.3%
202014.81%+10.5%
201913.40%-8.6%
201814.67%+0.9%
201714.54%+23.7%
201611.75%-